Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
142 participants
OBSERVATIONAL
2016-05-31
2017-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Early Administration of TXA in Adult Hip Fractures
NCT05047133
Does Early Administration of Tranexamic Acid Reduce Blood Loss and Perioperative Transfusion Requirement
NCT03182751
Effects of Tranexamic Acid on Blood Loss and Transfusion Requirement Following Hip Fracture
NCT02738073
Evaluation of TXA Prior to Surgery in the Geriatric Hip Fracture Population
NCT03923959
Tranexamic Acid in Intertrochanteric and Subtrochanteric Femur Fractures
NCT02580227
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tranexamic Acid
Patients that receive 2 gm TXA during surgery
No interventions assigned to this group
No Tranexamic Acid
Patients that receive no TXA during surgery
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 65 and older
* Low energy mechanism of injury
* Hip fracture fixation performed within 48 hours
* English speaking
* Anticipated medical optimization for operative fixation
* No other major trauma
Exclusion Criteria
* Infection around the affected hip
* Transfer patients with a length of stay \> 24 hours at the transferring hospital
* Diagnosis of deficient natural anticoagulation
* Known congenital thrombophilia (Deficiency of Protein C, S, Antithrombin)
* Known allergy to TXA
* Patients undergoing percutaneous pinning of the hip fracture
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Spectrum Health Hospitals
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Blake W Miller, DO
Role: PRINCIPAL_INVESTIGATOR
Spectrum Health Hospitals
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016-060
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.